Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Queensland Health
Accenture
Chubb
AstraZeneca
Cipla
Farmers Insurance
US Department of Justice
Cantor Fitzgerald
Cerilliant
Dow

Generated: October 21, 2017

DrugPatentWatch Database Preview

Pasireotide diaspartate - Generic Drug Details

« Back to Dashboard

What are the generic drug sources for pasireotide diaspartate and what is the scope of pasireotide diaspartate freedom to operate?

Pasireotide diaspartate
is the generic ingredient in one branded drug marketed by Novartis and is included in one NDA. There are two patents protecting this compound. Additional information is available in the individual branded drug profile pages.

Pasireotide diaspartate has eighty-five patent family members in thirty-eight countries and sixteen supplementary protection certificates in eleven countries.

One supplier is listed for this compound.

Summary for Generic Name: pasireotide diaspartate

US Patents:2
Tradenames:1
Applicants:1
NDAs:1
Suppliers / Packagers: see list1
Clinical Trials: see list60
Drug Prices:see low prices
DailyMed Link:pasireotide diaspartate at DailyMed

Pharmacology for Ingredient: pasireotide diaspartate

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Novartis
SIGNIFOR
pasireotide diaspartate
SOLUTION;SUBCUTANEOUS200677-001Dec 14, 2012RXYesNo► Subscribe► Subscribe► Subscribe
Novartis
SIGNIFOR
pasireotide diaspartate
SOLUTION;SUBCUTANEOUS200677-001Dec 14, 2012RXYesNo► Subscribe► SubscribeYY ► Subscribe
Novartis
SIGNIFOR
pasireotide diaspartate
SOLUTION;SUBCUTANEOUS200677-002Dec 14, 2012RXYesNo► Subscribe► SubscribeYY ► Subscribe
Novartis
SIGNIFOR
pasireotide diaspartate
SOLUTION;SUBCUTANEOUS200677-002Dec 14, 2012RXYesNo► Subscribe► Subscribe► Subscribe
Novartis
SIGNIFOR
pasireotide diaspartate
SOLUTION;SUBCUTANEOUS200677-001Dec 14, 2012RXYesNo► Subscribe► SubscribeYY ► Subscribe
Novartis
SIGNIFOR
pasireotide diaspartate
SOLUTION;SUBCUTANEOUS200677-003Dec 14, 2012RXYesYes► Subscribe► SubscribeYY ► Subscribe
Novartis
SIGNIFOR
pasireotide diaspartate
SOLUTION;SUBCUTANEOUS200677-002Dec 14, 2012RXYesNo► Subscribe► Subscribe► Subscribe
Novartis
SIGNIFOR
pasireotide diaspartate
SOLUTION;SUBCUTANEOUS200677-003Dec 14, 2012RXYesYes► Subscribe► SubscribeYY ► Subscribe
Novartis
SIGNIFOR
pasireotide diaspartate
SOLUTION;SUBCUTANEOUS200677-002Dec 14, 2012RXYesNo► Subscribe► SubscribeYY ► Subscribe
Novartis
SIGNIFOR
pasireotide diaspartate
SOLUTION;SUBCUTANEOUS200677-003Dec 14, 2012RXYesYes► Subscribe► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Expired Orange Book Patents for Generic Ingredient: pasireotide diaspartate

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Novartis
SIGNIFOR
pasireotide diaspartate
SOLUTION;SUBCUTANEOUS200677-002Dec 14, 2012► Subscribe► Subscribe
Novartis
SIGNIFOR
pasireotide diaspartate
SOLUTION;SUBCUTANEOUS200677-001Dec 14, 2012► Subscribe► Subscribe
Novartis
SIGNIFOR
pasireotide diaspartate
SOLUTION;SUBCUTANEOUS200677-003Dec 14, 2012► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Non-Orange Book Patents for Generic Ingredient: pasireotide diaspartate

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
7,939,625Somatostatin analogues► Subscribe
9,035,021Somatostatin analogues► Subscribe
8,822,637Somatostatin analogues► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Ingredient: pasireotide diaspartate

Country Document Number Estimated Expiration
Japan4746541► Subscribe
South Korea20060030052► Subscribe
Portugal1648934► Subscribe
Norway330706► Subscribe
Australia2001289778► Subscribe
Portugal1307486► Subscribe
Iceland2705► Subscribe
Austria393782► Subscribe
Spain2328144► Subscribe
Canada2529449► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

Supplementary Protection Certificates for Tradename: PASIREOTIDE DIASPARTATE

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
2012016,C1648934Lithuania► SubscribePRODUCT NAME: PASIREOTIDUM; REGISTRATION NO/DATE: EU/1/12/753/001 - EU/1/12/753/012, 0120424
0120019 00062Estonia► SubscribePRODUCT NAME: SIGNIFOR-PASIREOTIID;REG NO/DATE: C(2012) 2910 FINAL 24.04.2012
2012 00024Denmark► Subscribe
C/GB12/030United Kingdom► SubscribePRODUCT NAME: CYCLO((4R)-4-(2-AMINOETHYLCARBAMOYLOXY)-L-PROLYL-L-PHENYLGLYCYL-D-TRYPTOPHYL-L-LYSYL-4-O-BENZYL-L-TYROSYL-L-PHENYLALANYL-)), PASIREOTIDE, OR SALTS THEREOF; REGISTERED: UK EU/1/12/753/001-012 20120424
024Luxembourg► Subscribe92024, EXPIRES: 20260730
2012016Lithuania► SubscribePRODUCT NAME: PASIREOTIDUM; REGISTRATION NO/DATE: EU/1/12/753/001 - EU/1/12/753/012 20120424
12/027Ireland► SubscribePRODUCT NAME: PASIREOTIDE OR A SALT OR COMPLEX THEREOF; REGISTRATION NO/DATE: EU/1/12/753/001-EU/1/12/753/012 20120424
701Luxembourg► SubscribePRODUCT NAME: PASIREOTIDE OU UN SEL PHARMACEUTIQUEMENT ACCEPTABLE QUI EN DERIVE OU UN HYDRATE QUI EN DERIVE . FIRST REGISTRATION: 20141121
90022-1Sweden► SubscribePRODUCT NAME: PASIREOTID; REG. NO/DATE: EU/1/12/753/001 20120424
00716Netherlands► SubscribePRODUCT NAME: PASIREOTIDE OF EEN FARMACEUTISCH AANVAARDBAAR ZOUT DAARVAN OF EEN HYDRAAT DAARVAN; REGISTRATION NO/DATE: EU/1/12/753 20141119
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving leading biopharmaceutical companies globally:

Queensland Health
Novartis
Moodys
Boehringer Ingelheim
QuintilesIMS
Cerilliant
Chinese Patent Office
Healthtrust
Accenture
Covington

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot